Covid-19 ARDS Recruiting Phase 3 Trials for Baricitinib (DB11817)

Also known as: COVID19 ARDS

IndicationStatusPhase
DBCOND0135643 (Covid-19 ARDS)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04693026Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 PatientsTreatment